The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.
Study Type
OBSERVATIONAL
Enrollment
109
No intervention
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China
RECRUITINGOverall Survival (OS)
Time frame: Defined as the time from the date of randomization in the RATIONALE-307 trial to the date of death from any cause occurring on or before December 31, 2025.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.